Lineage Cell Therapeutics Profit Margin 1970-1969 | LCTX
Current and historical gross margin, operating margin and net profit margin for Lineage Cell Therapeutics (LCTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Lineage Cell Therapeutics net profit margin as of December 31, 1969 is -652.38%.
|Lineage Cell Therapeutics Annual Profit Margins
|Lineage Cell Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.